TABLE 3.
Factors | sLRP1 | CyPA | MMP9 | |||
|
|
|
||||
r | P | r | P | r | P | |
The whole sample | ||||||
MMSE | 0.167 | 0.152 | 0.066 | 0.571 | −0.128 | 0.276 |
MoCA | 0.169 | 0.149 | 0.077 | 0.514 | −0.182 | 0.123 |
Fazekas | 0.089 | 0.543 | 0.185 | 0.203 | 0.151 | 0.309 |
MTA | −0.010 | 0.945 | −0.086 | 0.558 | −0.007 | 0.961 |
The AD groups | ||||||
MMSE | 0.303 | 0.141 | 0.085 | 0.685 | 0.108 | 0.606 |
MoCA | 0.414 | 0.040* | 0.237 | 0.254 | −0.017 | 0.937 |
Fazekas | 0.053 | 0.797 | 0.259 | 0.201 | 0.167 | 0.416 |
MTA | 0.346 | 0.083 | 0.464 | 0.017* | 0.000 | 1.000 |
The SIVD groups | ||||||
MMSE | 0.314 | 0.145 | −0.139 | 0.527 | −0.325 | 0.140 |
MoCA | 0.228 | 0.308 | −0.397 | 0.067 | −0.528 | 0.014* |
Fazekas | 0.001 | 0.998 | 0.195 | 0.398 | −0.248 | 0.278 |
MTA | 0.197 | 0.367 | −0.157 | 0.476 | 0.142 | 0.529 |
Adjusted for age, sex, and education.
*The correlation of plasma biomarker levels with cognitive scores and imaging parameters, the difference was significant (p < 0.05).